Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Amgen is flush with +$20 billion in cash, likely interested in buying ADXS but our Board won't sell at such the low value we've dropped to. But, as others have said, I could see Amgen expanding its deal with ADXS, either to include AXAL or HOT, and upping its equity stake in ADXS, hence the need for more authorized shares, plus an upfront cash payment. Amgen increasing its equity stake, even if it's at $3 a share, would be a good thing as it would 1) address our dwindling cash issue, and 2) would be a huge endorsement and boost of confident that Amgen is step by step looking to buy ADXS and should reset our movement back up toward fair value.